# Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

> **NCT00740584** · PHASE1,PHASE2 · COMPLETED · sponsor: **Starpharma Pty Ltd** · enrollment: 12 (actual)

## Conditions studied

- HIV Infections
- HSV-2 Genital Herpes

## Interventions

- **DRUG:** 3% SPL7013 Gel (VivaGel)

## Key facts

- **NCT ID:** NCT00740584
- **Lead sponsor:** Starpharma Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740584, "Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00740584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*